APYX apyxmedical.com: מקדם חוב לטווח ארוך להון

FDA regulatory claims and patient lawsuits are weighing on Apyx Medical (APYX) margins. The current long-term debt-to-equity ratio demonstrates financial stability, where the 3.78 mark characterizes this parameter. Apyx Medical generates revenue from the sale of Renuvion systems for aesthetic medicine, although geopolitical instability and electronics supply chain disruptions from Asia are limiting the brand's global expansion.

This metric assesses the business's reliance on long-term borrowings relative to its equity. For Apyx Medical (APYX), this reflects the cost of financing the development of Helium cold plasma technologies. By analyzing the long-term debt structure ratio, one can evaluate the sustainability of the FDA protocol expansion. The metric reveals the balance between debt load and net profit. Low leverage here confirms a conservative approach to the evolution of the devices.